News Release

COVID-19 rebound after VV116 vs nirmatrelvir-ritonavir treatment

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this randomized clinical trial of 345 patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound were both common after a standard 5-day course of antiviral treatment with either VV116 or nirmatrelvir-ritonavir. Prolongation of treatment duration might be investigated to reduce COVID-19 rebound. 

Authors: Yufang Bi, M.D., and Yiping Xu, M.Sc., of the Shanghai Jiao Tong University School of Medicine in Shanghai, China, are the corresponding authors. 

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.